Concepedia

Michael Rytting

MR

55

Publications

5.1K

Citations

34

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

St. Jude Children's Research Hospital

Memorial Sloan Kettering Cancer Center

The University of Texas Health Science Center at Houston

Children's Hospital of Los Angeles

Michael Rytting is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top concepts

Publications per year

1999–2021

55

Publications

55

Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González et al. · Blood · 2006 · 467 citations · Full text

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology · 2012 · 410 citations

, , +12

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Nitin Jain, Audrey Lamb, Susan O’Brien et al. · Blood · 2016 · 338 citations · Full text

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

Sima Jeha, Paul S. Gaynon, Bassem I. Razzouk et al. · Journal of Clinical Oncology · 2006 · 304 citations · Full text

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · Cancer · 2013 · 298 citations · Full text

Rows per page

1–5 of 55